Skip to main navigation Skip to search Skip to main content

C1-BYPASS COMPLEMENT-ACTIVATION PATHWAY IN PATIENTS WITH CHRONIC URTICARIA AND ANGIO-ŒDEMA

  • Mark Ballow
  • , George W. Ward
  • , M. Eric Gershwin
  • , Noorbibi K. Day
  • Walter Reed National Military Medical Center
  • University of California at Davis
  • Memorial Sloan-Kettering Cancer Center

Research output: Contribution to journalArticlepeer-review

32 Scopus citations

Abstract

During the routine screening of 152 patients with urticaria or angio-œdema for hypocomplementæmia, 4 patients were found to have low serum levels of the third component of complement (C). These patients were noteworthy and differed from previous reports of patients with urticaria-like skin lesions and hypocomplementæmia because of the absence of immune-complex disease. In addition to the low C3, 2 of these patients were unique on the basis of low serum levels of hæmolytic Cl, Clq, Cls, and properdin factor B, but normal concentrations of C4 and C2. These C abnormalities may reflect a new clinical entity, and these cases form the first description in man of the C1-bypass complement-activation pathway.

Original languageEnglish
Pages (from-to)248-250
Number of pages3
JournalThe Lancet
Volume306
Issue number7928
DOIs
StatePublished - Aug 9 1975

Fingerprint

Dive into the research topics of 'C1-BYPASS COMPLEMENT-ACTIVATION PATHWAY IN PATIENTS WITH CHRONIC URTICARIA AND ANGIO-ŒDEMA'. Together they form a unique fingerprint.

Cite this